-
Product Insights
Acinetobacter Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Acinetobacter Infections - Drugs In Development, 2023’, provides an overview of the Acinetobacter Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acinetobacter Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Drugs In Development, 2023’, provides an overview of the Methicillin-Resistant Staphylococcus aureus (MRSA) Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Rotavirus Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Rotavirus Infections - Drugs In Development, 2023’, provides an overview of the Rotavirus Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Rotavirus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Histology And Cytology Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies
Histology and Cytology Pipeline Market Report Overview Histology and Cytology consist of reagents and test kits used in tissue and cell typing techniques. Reagents like monoclonal antibodies, polyclonal antibodies, immunomodulators, and tissue typing reagents have been tracked under this category in the report. Apart from reagents flow cytometry reagents are also tracked. The Histology and Cytology pipeline market research report provides comprehensive information about the Histology and Cytology pipeline products with a comparative analysis of the products at various stages...
-
Product Insights
NewNet Present Value Model: Xencor Inc’s Vibecotamab
Empower your strategies with our Net Present Value Model: Xencor Inc's Vibecotamab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lifirafenib Maleate in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lifirafenib Maleate in Endometrial Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lifirafenib Maleate in Endometrial Cancer Drug Details: Lifirafenib maleate is under...
-
Product Insights
NewNet Present Value Model: Aridis Pharmaceuticals Inc’s Suvratoxumab
Empower your strategies with our Net Present Value Model: Aridis Pharmaceuticals Inc's Suvratoxumab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Iterum Therapeutics Plc’s Sulopenem Etzadroxil
Empower your strategies with our Net Present Value Model: Iterum Therapeutics Plc's Sulopenem Etzadroxil report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Aridis Pharmaceuticals Inc’s Aerumab
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
NewNet Present Value Model: Aridis Pharmaceuticals Inc’s Salvecin
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.